Takeda, Tsuyoshi
Sasaki, Takashi https://orcid.org/0000-0001-7109-9835
Fukuda, Koshiro
Mie, Takafumi
Furukawa, Takaaki
Yamada, Yuto
Kasuga, Akiyoshi
Matsuyama, Masato
Ozaka, Masato
Sasahira, Naoki
Article History
Received: 30 June 2020
Accepted: 29 October 2020
First Online: 11 November 2020
Compliance with ethical standards
:
: All authors declare no conflicts of interests for this article. Conflicts of interests outside this work are as follows; Naoki Sasahira received research funding from Zeria, Eisai, Kyowa Hakko Kirin, Baxalta and Taiho Pharmaceutical. Masato Ozaka received honoraria from Taiho Pharmaceutical, Yakult, Bayer, Pfizer, Novartis, Takeda Pharmaceutical Company Limited, Eisai, EA pharma and Mitsubishi Tanabe Pharma Corporation and research funding from Merck & Co., Inc., Incyte, ASLAN Pharmaceuticals, Taiho Pharmaceutical and Yakult. Takashi Sasaki received honoraria from Taiho Pharmaceutical and Eisai.
: This study was approved by the ethics committee of our institution (Institutional Review Board number: 2020-1041).